Biotech selling Arikayce for a rare lung infection and developing therapies for bronchiectasis and other rare respiratory diseases.
Biotech selling Arikayce for a rare lung infection and developing therapies for bronchiectasis and other rare respiratory diseases.
Until 2025 earned all its revenue from Arikayce, an inhaled antibiotic for a rare lung infection, sold mainly in the US with some sales in Japan and Europe. Brensocatib, branded Brinsupri, was approved in the US in 2025 for bronchiectasis, a far bigger patient group, making it a company with a second product to launch. It is still loss-making.
Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and specialist prescriber relationships in a very small patient population.
Headquarters: Bridgewater, New Jersey, United States · Founded: 1988 · Employees: 1,664
Size Insmed (INSM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $26.3B, the 411th largest of 3,085 United States companies the cockpit tracks. Shares closed at $119.80 on 18 Nov 2026.
Performance Over six months the shares gained 3.3%, against +10.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.
Growth Revenue grew 240.0% over the last twelve months (peer median +20.1%); the operating margin is -41.7% (peer median 18.9%).
Valuation It trades at 17.0× enterprise value to sales against a peer median of 4.4× (4th most expensive of 21).
Capital Return on invested capital runs 161.0 points below its cost of capital (9.1% WACC).
Short interest Short interest is 6.4% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.52B | $606M | $364M | $305M | $245M |
| Revenue growth | — | +67% | +19% | +24% | — |
| Gross profit | $1.27B | $477M | $273M | $235M | $185M |
| EBITDA | -$607M | -$978M | -$776M | -$670M | -$454M |
| Net income | -$606M | -$1.28B | -$914M | -$750M | -$482M |
| Free cash flow | -$658M | -$998M | -$706M | -$550M | -$410M |
| Capital expenditure | $62.0M | $62.6M | $21.9M | $13.3M | $9.88M |
| Total debt | $750M | $756M | $1.31B | $1.36B | $1.33B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Insmed INSM | $26.3B | +3% | +240% | -42% | 17.0× | n/a |
| Vertex Pharmaceuticals VRTX | $136B | +25% | +11% | 35% | 10.5× | 6.2% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 5.0× | 14.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | INSM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.2% | +4.5% | highest of 21 |
| 6-month return | +3.3% | +10.7% | 6th lowest of 21 |
| Distance from 52-week high | -43.7% | -9.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | +240.0% | +20.1% | highest of 21 |
| Operating margin | -41.7% | 18.9% | 2nd lowest of 21 |
| EV / Sales | 17.0× | 4.4× | 4th most expensive of 21 |
| ROIC minus cost of capital | -161.0 pp | +5.4 pp | lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | 17.0× | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 9.0× | 7.9% | +10.8% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | 597.3× | n/a | n/a |
| Incyte INCY | United States | $24.0B | +21% | +25% | 12% | 3.4× | 14.2% | +14.0% |
| Viatris VTRS | United States | $23.3B | +23% | +5% | 11% | 2.4× | 11.2% | +3.7% |
| Sigma Healthcare SIG.AX | Australia | $22.4B | +2% | +209% | 9% | 3.3× | 28.9% | +26.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 23.8× | 47.1% | +8.9% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 2.1× | 7.6% | +17.1% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 2.2× | -9.0% | +11.4% |
| Alnylam Pharmaceuticals ALNY | United States | $20.0B | -50% | +56% | 20% | 3.9× | 0.5% | +49.8% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 4.5× | -2.9% | +7.2% |
| Innovent Biologics 1801.HK | Hong Kong | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% | +26.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | India | $18.8B | +3% | +42% | 22% | 10.7× | 37.6% | +11.3% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 4.4× | 10.1% | -5.1% |
| Shionogi & 4507.T | Japan | $17.6B | +3% | +46% | 29% | 4.9× | 0.2% | +11.0% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 19.3× | 10.8% | +2.3% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 3.4× | 5.2% | +2.2% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 2.3× | 1.6% | +11.7% |
| Ascendis Pharma A/S ASND | United States | $16.9B | +12% | +94% | 18% | 11.7× | 19.2% | +152.4% |
| Exelixis EXEL | United States | $16.7B | +37% | +9% | 40% | 6.4× | -3.8% | +18.6% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 4.2× | 7.5% | +0.4% |